Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease:
Gespeichert in:
| Beteiligte Personen: | , , , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Veröffentlicht: |
Erlangen
Friedrich-Alexander-Universität Erlangen-Nürnberg
2019
|
| Schlagwörter: | |
| Links: | https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-121416 https://d-nb.info/1194651267/34 https://open.fau.de/handle/openfau/12141 |
| Umfang: | 1 Online-Ressource |
Internformat
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046428147 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 200217s2019 gw o|||| 00||| eng d | ||
| 015 | |a 19,O10 |2 dnb | ||
| 016 | 7 | |a 1194651267 |2 DE-101 | |
| 024 | 7 | |a urn:nbn:de:bvb:29-opus4-121416 |2 urn | |
| 035 | |a (OCoLC)1141121400 | ||
| 035 | |a (DE-599)DNB1194651267 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BY | ||
| 049 | |a DE-29 | ||
| 084 | |a 616.83 |2 sdnb | ||
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Hansson, Oskar |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease |c Oskar Hansson, Sylvain Lehmann, Markus Otto, Henrik Zetterberg, Piotr Lewczuk |
| 264 | 1 | |a Erlangen |b Friedrich-Alexander-Universität Erlangen-Nürnberg |c 2019 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 583 | 1 | |a Archivierung/Langzeitarchivierung gewährleistet |5 DE-101 |2 pdager | |
| 653 | |a Alzheimer’s Disease | ||
| 653 | |a Amyloidβ Peptides | ||
| 653 | |a Aβ42/40 ratio | ||
| 653 | |a Biomarkers | ||
| 653 | |a Cerebrospinal Fluid | ||
| 700 | 1 | |a Lehmann, Sylvain |e Verfasser |4 aut | |
| 700 | 1 | |a Otto, Markus |e Verfasser |4 aut | |
| 700 | 1 | |a Zetterberg, Henrik |e Verfasser |4 aut | |
| 700 | 1 | |a Lewczuk, Piotr |e Verfasser |4 aut | |
| 787 | 0 | 8 | |i Sonderdruck aus |t Alzheimer's Research & Therapy |g Vol. 11 (2019) |o 10.1186/s13195-019-0485-0 |
| 856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-121416 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://d-nb.info/1194651267/34 |x Langzeitarchivierung Nationalbibliothek |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://open.fau.de/handle/openfau/12141 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ebook | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031840434 | |
Datensatz im Suchindex
| _version_ | 1818986511640559616 |
|---|---|
| any_adam_object | |
| author | Hansson, Oskar Lehmann, Sylvain Otto, Markus Zetterberg, Henrik Lewczuk, Piotr |
| author_facet | Hansson, Oskar Lehmann, Sylvain Otto, Markus Zetterberg, Henrik Lewczuk, Piotr |
| author_role | aut aut aut aut aut |
| author_sort | Hansson, Oskar |
| author_variant | o h oh s l sl m o mo h z hz p l pl |
| building | Verbundindex |
| bvnumber | BV046428147 |
| collection | ebook |
| ctrlnum | (OCoLC)1141121400 (DE-599)DNB1194651267 |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01931nam a2200493zc 4500</leader><controlfield tag="001">BV046428147</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">200217s2019 gw o|||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">19,O10</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1194651267</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">urn:nbn:de:bvb:29-opus4-121416</subfield><subfield code="2">urn</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1141121400</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1194651267</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BY</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">616.83</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hansson, Oskar</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease</subfield><subfield code="c">Oskar Hansson, Sylvain Lehmann, Markus Otto, Henrik Zetterberg, Piotr Lewczuk</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Erlangen</subfield><subfield code="b">Friedrich-Alexander-Universität Erlangen-Nürnberg</subfield><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="583" ind1="1" ind2=" "><subfield code="a">Archivierung/Langzeitarchivierung gewährleistet</subfield><subfield code="5">DE-101</subfield><subfield code="2">pdager</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Alzheimer’s Disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Amyloidβ Peptides</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Aβ42/40 ratio</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cerebrospinal Fluid</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lehmann, Sylvain</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Otto, Markus</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zetterberg, Henrik</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lewczuk, Piotr</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="787" ind1="0" ind2="8"><subfield code="i">Sonderdruck aus</subfield><subfield code="t">Alzheimer's Research & Therapy</subfield><subfield code="g">Vol. 11 (2019)</subfield><subfield code="o">10.1186/s13195-019-0485-0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-121416</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://d-nb.info/1194651267/34</subfield><subfield code="x">Langzeitarchivierung Nationalbibliothek</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://open.fau.de/handle/openfau/12141</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031840434</subfield></datafield></record></collection> |
| id | DE-604.BV046428147 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-20T18:51:58Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031840434 |
| oclc_num | 1141121400 |
| open_access_boolean | 1 |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | 1 Online-Ressource |
| psigel | ebook |
| publishDate | 2019 |
| publishDateSearch | 2019 |
| publishDateSort | 2019 |
| publisher | Friedrich-Alexander-Universität Erlangen-Nürnberg |
| record_format | marc |
| spelling | Hansson, Oskar Verfasser aut Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease Oskar Hansson, Sylvain Lehmann, Markus Otto, Henrik Zetterberg, Piotr Lewczuk Erlangen Friedrich-Alexander-Universität Erlangen-Nürnberg 2019 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Archivierung/Langzeitarchivierung gewährleistet DE-101 pdager Alzheimer’s Disease Amyloidβ Peptides Aβ42/40 ratio Biomarkers Cerebrospinal Fluid Lehmann, Sylvain Verfasser aut Otto, Markus Verfasser aut Zetterberg, Henrik Verfasser aut Lewczuk, Piotr Verfasser aut Sonderdruck aus Alzheimer's Research & Therapy Vol. 11 (2019) 10.1186/s13195-019-0485-0 https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-121416 Resolving-System kostenfrei Volltext https://d-nb.info/1194651267/34 Langzeitarchivierung Nationalbibliothek kostenfrei Volltext https://open.fau.de/handle/openfau/12141 Verlag kostenfrei Volltext |
| spellingShingle | Hansson, Oskar Lehmann, Sylvain Otto, Markus Zetterberg, Henrik Lewczuk, Piotr Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease |
| title | Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease |
| title_auth | Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease |
| title_exact_search | Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease |
| title_full | Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease Oskar Hansson, Sylvain Lehmann, Markus Otto, Henrik Zetterberg, Piotr Lewczuk |
| title_fullStr | Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease Oskar Hansson, Sylvain Lehmann, Markus Otto, Henrik Zetterberg, Piotr Lewczuk |
| title_full_unstemmed | Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease Oskar Hansson, Sylvain Lehmann, Markus Otto, Henrik Zetterberg, Piotr Lewczuk |
| title_short | Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease |
| title_sort | advantages and disadvantages of the use of the csf amyloid β aβ 42 40 ratio in the diagnosis of alzheimer s disease |
| url | https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-121416 https://d-nb.info/1194651267/34 https://open.fau.de/handle/openfau/12141 |
| work_keys_str_mv | AT hanssonoskar advantagesanddisadvantagesoftheuseofthecsfamyloidbab4240ratiointhediagnosisofalzheimersdisease AT lehmannsylvain advantagesanddisadvantagesoftheuseofthecsfamyloidbab4240ratiointhediagnosisofalzheimersdisease AT ottomarkus advantagesanddisadvantagesoftheuseofthecsfamyloidbab4240ratiointhediagnosisofalzheimersdisease AT zetterberghenrik advantagesanddisadvantagesoftheuseofthecsfamyloidbab4240ratiointhediagnosisofalzheimersdisease AT lewczukpiotr advantagesanddisadvantagesoftheuseofthecsfamyloidbab4240ratiointhediagnosisofalzheimersdisease |